CHP
DNLI icon

Cable Hill Partners’s Denali Therapeutics DNLI Stock Holding History

Cable Hill Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-300
Closed -$7K – 256
2019
Q1 		$7K Hold
300
– – ﹤0.01% 533
2018
Q4 		$6K Buy
+300
New +$5.44K ﹤0.01% 525

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Cable Hill Partners's DNLI Position: Q2 2019 in Review

Cable Hill Partners sold out of Denali Therapeutics (DNLI) in Q2 2019, closing a stake of 300 shares — an estimated $7K sold.

Cable Hill Partners first reported a position in DNLI in Q4 2018 and held it in 2 quarters. The position peaked at $7K in Q1 2019. 114 funds tracked by Wall St. Rank hold DNLI as of Q2 2019.

  • Cable Hill Partners reported no remaining Denali Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Cable Hill Partners sold 300 Denali Therapeutics shares in Q2 2019, an estimated $7K.
  • Cable Hill Partners first reported a position in Denali Therapeutics in Q4 2018 and held it in 2 quarters.
  • Cable Hill Partners's Denali Therapeutics position peaked at $7K in Q1 2019.
  • 114 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.